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We examined the effects of lactate on the enzymatic activity of hexokinase (HK), phosphofructoki-
nase (PFK) and pyruvate kinase (PK) in various mouse tissues. Our results showed that lactate inhib-
ited PFK activity in all the analyzed tissues. This inhibitory effect was observed in skeletal muscle
even in the presence of insulin. Lactate directly inhibited the phosphorylation of PFK tyrosine res-
idues in skeletal muscle, an important mechanism of the enzyme activation. Moreover, lactate indi-
rectly inhibited HK activity, which resulted from its cellular redistribution, here attributed to
alterations of HK structure. PK activity was not affected by lactate. The activity of HK and PFK is
directly related to glucose metabolism. Thus, it is conceivable that lactate exposure can induce inhi-
bition of glucose consumption in tissues.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
In the last century, lactate had been considered as the end prod-
uct of glycolytic ﬂux with no major metabolic functions other than
inducing metabolic acidosis and tissue damage [1,2]. However, in
recent years, lactate has been studied based on its ability to serve
as an energy source and a cell-signaling and tissue-repairing mol-
ecule [1,3]. Chronic hyperlactatemia has been described as an inde-
pendent risk factor for diabetes development, with lactate being an
important factor for maintaining insulin resistance [4,5]. To date,
only a few metabolic explanations have been provided for this ef-
fect of lactate. Depré et al. reported decreased tissue glucose con-
sumption in the presence of lactate [6]. Lombardi et al. proposed
that hyperlactatemia could decrease the GLUT-4 level and glucose
uptake by skeletal muscle [7], a rate-limiting step of glucose
metabolism in skeletal muscle. In addition, Choi et al. demon-
strated that lactate could induce insulin resistance in skeletal mus-
cle by inhibiting glycolytic ﬂux through suppressing insulin
signaling [8]. However, they did not specify which step(s) of the
glycolytic ﬂux was (were) inhibited. In a previous study, weal Societies. Published by Elsevier
Enzimologia e Controle do
os, Faculdade de Farmácia,
o, Rio de Janeiro – RJ 21941-demonstrated that lactate could inhibit 6-phosphofructo-1-kinase
(PFK, phosphofructokinase), a regulatory enzyme of glycolytic ﬂux,
by dissociating the active enzyme tetramers into the less active di-
mers [9].
This study aimed to contribute to, and to expand the knowledge
regarding, the action mechanism of lactate in skeletal muscle, liver,
kidney and heart. Our results demonstrate that lactate can inhibit
both hexokinase (HK) and PFK, but not pyruvate kinase (PK) in a
variety of tissues, supporting the hypothesis of negative regulation
of glucose consumption by glycolytic ﬂux downregulation.2. Materials and methods
2.1. Materials
ATP, fructose-6-phosphate, fructose-2,6-biphosphate (F2,6BP),
hexokinase, insulin and glucose were obtained from Sigma Chem-
ical Co. (St. Louis, MO, USA). 32Pi was obtained from the Instituto de
Pesquisas Energéticas e Nucleares (São Paulo, Brazil). [c-32P]ATP
was prepared according to Maia et al. [10].
2.2. Mouse tissue homogenates
All mouse Experiments were performed according to the animal
experimental protocols. Male Swiss mice (20–25 g) fed ad libitumB.V. Open access under the Elsevier OA license.
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quadriceps were promptly removed, stripped of fat and connective
tissue and incubated in the homogenization buffer consisting of
50 mM Tris–HCl (pH 7.4), 250 mM sucrose, 20 mM KF, 0.2 mM b-
mercaptoethanol and 0.5 mM PMSF (1:3). The tissues were then
treated with or without 5 or 10 mM lactate, depending on the
requirements of the experiments.
2.3. Tissue fractionation
Tissue fractionation was performed according to a modiﬁcation
of the Lilling and Beitner protocol [11] proposed by Alves and Sola-
Penna [12]. The pH of all tissues homogenate and fractions were
controlled before and after the addition of lactate to assure that
the pH was controlled.
2.4. Enzymatic activity assays
HK and PFK enzymatic activities were assessed by the
radiometric method described by Sola-Penna et al. [13] with
the modiﬁcations proposed by Zancan and Sola-Penna [14,15].
This assay was performed at 37 C in a 0.4-ml reaction system
containing 50 mM Tris–HCl (pH 7.4), 5 mM MgCl2 and
[c-32P]ATP (4 lCi/lmol). PK was evaluated in a basic medium
containing 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 5 mM
phospho(enol)pyruvate (PEP), 5 mM ADP and 120 mM KCl. The
reaction was initiated by the addition of enzyme preparation.
Aliquots were withdrawn 2, 4, 6, 8 and 10 min after the reaction
was initiated and the reaction was stopped by the addition of
0.1 N HCl. The medium was neutralized with NaOH and the
ATP content was evaluated using the commercial kit ATPlite 1
step (PerkinElmer, MA, USA). Blanks were performed in parallel
in the absence of PEP.
2.5. Intrinsic ﬂuorescence spectroscopy
Intrinsic ﬂuorescence analysis was perfumed on a spectroﬂuo-
rimeter (Jasco ) in media consisting of 100 mM Tris–HCl (pH
7.4), 5 mM (NH4)2SO4 and puriﬁed hexokinase (5 lg/ml) in the
presence or absence of 5 or 10 mM lactate. Respective spectra were
subtracted for background and interference correction. The excita-
tion wavelength used was 280 nm, and ﬂuorescence emission was
scanned from 300 to 400 nm (0.5 nm intervals at a rate of 100 nm/
min). The center of mass of the intrinsic ﬂuorescence spectrumwas
calculated according to Leite et al. [9] using the SigmaPlot 10.0 (Sy-
stat) software.
2.6. Immunoprecipitation and Western blotting
Immunoprecipitation and western blotting were performed as
previously described [16], using a polyclonal anti-PFK antibody
produced in our laboratory according to Meira et al. [17] and a
monoclonal anti-phosphotyrosine antibody (clone pT-154, Sigma
Chemical Co, MO, USA). Brieﬂy, homogenates from tissues from
mice were treated with or without 10 mM lactate in the presence
or absence of 100 nM insulin for 3 h. Subsequently, the treated
homogenates were subjected to analysis.
2.7. Statistical analysis
Results are expressed as the mean ± standard error of the mean
(S.E.M.). Statistical analysis was performed using the SigmaPlot
software (v.10.0, Systat Inc., CA, USA) integrated with SigmaStat
(v. 3.2, Systat Inc. CA, USA). We used the Student t-test to compare
different groups, and P < 0.05 was considered statistically
signiﬁcant.3. Results and discussion
3.1. Effects of lactate on PFK activity
We assessed the ability of lactate to modulate PFK and found
that lactate inhibited PFK activity in the analyzed tissues under sev-
eral conditions (Fig. 1). Acute exposure to 10 mM lactate exerted no
effect on PFK activity in skeletal and cardiac muscle. However, we
observed a 20% and 33% reduction in PFK activity in the liver and
kidney, respectively. Unlike the acute exposure to 10 mM lactate,
lactate preincubation for three hours inhibited PFK activity in skel-
etal and cardiac muscle. However, in the liver and kidney, lactate
preincubation did not cause a further decrease in PFK activity. To
evaluate if the ability of lactate to inhibit PFK activity remains in
the presence of hormones that stimulate glycolytic ﬂux, isolated
mouse tissues were incubated in a buffer containing 4.5 mM glu-
cose and stimulated with 100 nM insulin (Fig. 1). We observed that
after insulin exposure, the ability of lactate to inhibit PFK was lost,
independent of the analyzed tissue type and time frame. The only
exception was found in skeletal muscle, where we observed a 52%
reduction in PFK activity in the tissue preincubated with 10 mM
lactate, even in the presence of 100 nM insulin (Fig. 1). Insulin
can promote an increase in intracellular synthesis of F2,6BP, a
known positive allosteric factor of PFK [18,19]. Therefore, it is pos-
sible that the increased F2,6BP synthesis triggered by insulin could
counterbalance the inhibitory effect of lactate on PFK activity.
To evaluate whether F2,6BP is capable of reversing the inhibi-
tory effect of lactate on PFK activity, isolated mouse tissues were
preincubated with or without 10 mM lactate for three hours and
subsequently treated with 100 nM F2,6BP (Fig. 2). As expected,
PFK was activated when tissues were treated with 100 nM
F2,6BP. As shown in Fig. 2, PFK activity in skeletal muscle, heart, li-
ver and kidney was increased by approximately 148%, 156%, 132%
and 134%, respectively. However, the stimulatory effect of
F2,6BPF2, 6BP on PFK activity was decreased by preincubating
the tissues with lactate for three hours. Under these conditions,
PFK activity in skeletal muscle, heart, liver and kidney was approx-
imately 70%, 121%, 104% and 96%, respectively, of the levels ob-
served in control samples. Only in skeletal muscle was the PFK
activity signiﬁcantly lower than that in the control samples.
It has been shown that PFK is regulated by different protein ki-
nases capable of phosphorylating its serine, threonine and/or tyro-
sine residues [20–22]. Therefore, we proceeded to examine if
lactate is capable of regulating the phosphorylation levels of these
residues in PFK. For this purpose, skeletal and cardiac muscle, as
well as liver and kidney tissues, was incubated for three hours with
10 mM lactate or 100 mM insulin (positive control) for evaluating
the PFK phosphorylation levels. As expected, insulin stimulation
led to an increase in PFK phosphorylation in all the analyzed tis-
sues (Fig. 3). The representative western blot in Fig. 3 showed that
previous exposure of the tissues to 10 mM lactate for three hours
caused a 40% decrease in PFK tyrosine phosphorylation level only
in skeletal muscle. Phosphorylation of serine and threonine resi-
dues, however, was not altered under these conditions indepen-
dent of the analyzed tissue type (data not shown). These data
indicate that lactate can inhibit PFK activity through both a direct
effect independent of the insulin signaling cascade (by inhibiting
PFK phosphorylation) and an antagonistic effect to the insulin sig-
naling cascade (by counteracting the effects of F2,6BP).3.2. Effects of lactate on hexokinase/glucokinase activity
Another possible action mechanism of glycolytic ﬂux inhibition
by lactate is its ability to modulate hexokinase, another enzyme in-
volved in controlling the ﬂux. To evaluate the role of lactate in
Fig. 1. Effect of lactate on PFK activity in mouse tissue homogenates. Tissues were isolated and preincubated for 3 h in the presence or absence of 10 mM lactate and/or
100 nM insulin. After incubation, the tissues were homogenized, and PFK activity was measured. Pre-incubation with lactate affected the PFK activity in all the analyzed
tissues, with the renal and hepatic tissues being sensitive to lactate independent of the exposure time. Only in skeletal muscle was PFK activity modulated by lactate in the
presence of insulin. Values are presented as the mean ± S.E.M. of at least ﬁve independent experiments. *P < 0.05 indicates a statistically signiﬁcant difference between the
treated sample and the respective control in the absence of lactate (black bars).
Fig. 2. Effect of lactate on PFK stimulation by F2,6BP (F26BP). Tissues were isolated
and preincubated in the presence or absence of 10 mM lactate for three hours. After
incubation, the tissues were homogenized and stimulated with 100 nM F26BP, and
PFK activity was measured. Preincubation with lactate led to a decrease in the
stimulatory effect of F26BP on PFK activity in all the analyzed tissues. Values are
presented as the mean ± S.E.M. of at least ﬁve independent experiments. *P < 0.05
indicates a statistically signiﬁcant difference between the group stimulated with
F26BP and the group stimulated with F26BP pre-treated with lactate. **P < 0.05
indicates a statistically signiﬁcant difference between the control group (black bars)
and the group pre-treated with lactate and F26BP.
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submitted to different treatments as indicated in Fig. 4. Lactate did
not modulate hexokinase activity in the heart or kidney (data not
shown). Similar to what we observed for PFK activity, acute expo-
sure to 10 mM lactate inhibited hexokinase activity in skeletal
muscle (Fig. 4A). Exposure of skeletal muscle to 100 nM insulin in-
creased hexokinase activity by ﬁve folds. However, we found that
the stimulatory effect on hexokinase activity was completely abol-
ished by simultaneous treatment with 100 nM insulin and 10 mM
lactate for three hours: the activity levels were similar to those ob-
served in controls (Fig. 4A).
Another hexokinase isoform, hexokinase IV or glucokinase, is
present in the liver. To evaluate the modulation of glucokinase
by lactate, mouse livers were preincubated with 100 nM insulin
and 10 mM lactate for 3 h. We observed that lactate inhibited glu-
cokinase activity independent of the glucose concentration used
(Fig. 4B). These results suggest that lactate can affect glucose
metabolism in both skeletal muscle and hepatic tissue by at least
two distinct mechanisms, i.e., PFK inhibition and hexokinase (glu-
cokinase) inhibition. The inhibition of glucokinase, even in the
presence of insulin, suggests that lactate, in addition to being a
substrate for gluconeogenesis, can also act as a positive modulator
of this metabolic pathway. We suggest that lactate is not only a
substrate for gluconeogenesis but also capable of inhibiting both
PFK (Fig. 1) and glucokinase (Fig. 4), two of the most important en-
zymes regulating hepatic glucose consumption.
Fig. 3. Effect of lactate on phosphorylation level of PFK tyrosine residues. Tissues were isolated and preincubated for 3 h in the presence or absence of 10 mM lactate and/or
100 nM insulin for analyzing the phosphorylation levels of PFK tyrosine residues. (A) Western blot of different tissues blotted with an anti-phosphotyrosine antibody (1:
control; 2: 10 mM lactate; 3: 100 nM insulin). (B) Phosphate incorporation in tyrosine residues normalized to total PFK. Exposure to 10 mM lactate for 3 h decreased the
overall phosphorylation level of PFK tyrosine residues in skeletal muscle. Insulin treatment promotes an increase in the phosphorylation level of PFK tyrosine residues in all
the analyzed tissues.
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nase and glucokinase activity, we evaluated its ability to modulate
the intracellular sublocalization of these enzymes. The binding of
hexokinase I to mitochondria renders the enzyme less susceptible
to the inhibition by its product [6]. In order to evaluate the cellular
distribution of hexokinase in the presence of 10 mM of lactate,
mouse tissues were isolated and subjected to differential centrifu-
gation. We analyzed the enzymatic activity in two fractions, total
homogenate (TH) and the mitochondria and nuclear compart-
ment-enriched fraction (P1). As shown in Fig. 4C, lactate inhibited
hexokinase activity in TH from skeletal muscle and liver, which
was likely associated with cellular redistribution of hexokinase be-
cause we observed signiﬁcant hexokinase inhibition in the P1 frac-
tion from both tissues (Fig. 4C). Lactate did not modulate the
activity or the cellular distribution of hexokinase in the heart and
kidney (data not shown).
We next evaluated the ability of lactate to inhibit the hexoki-
nase activity stimulated by increasing concentrations of the P1
fraction. For this purpose, the activity of puriﬁed hexokinase was
determined in the presence or absence of 10 mM lactate in the
P1 fraction from skeletal muscle, heart, liver and kidney. Fig. 5
showed the activity of puriﬁed hexokinase in the presence of the
mitochondria-enriched P1 fraction from skeletal muscle. We noted
that even the P1 fraction at the lowest analyzed concentration
(1 lg/ml) was sufﬁcient to saturate the activity of the puriﬁedhexokinase. The same activation pattern was observed in all the
analyzed tissues (data not shown). We suggest that binding of
the enzyme to mitochondria and the subsequent auto-activation
caused the 4.5-fold increase in activity.
We further evaluated whether the hexokinase inhibition by lac-
tate is direct, similar to that of PFK inhibition [9]. For this purpose,
we performed an assay using puriﬁed hexokinase in the presence
of different concentrations of glucose in the presence or absence
of 10 mM lactate (Fig. 6A). The data showed that lactate did not
modulate the activity of the puriﬁed hexokinase because it did
not alter its afﬁnity for glucose or ATP (data not shown). Together
with the data shown in Figs. 4 and 5, these results suggest that lac-
tate inhibits hexokinase activity by dissociating the enzyme from
mitochondria or nuclei, rather than by a direct inhibition. Even
though lactate does not directly inhibit hexokinase, it could indi-
rectly inhibit hexokinase activity by mobilizing it to the soluble
fraction. It is possible that lactate could cause enzyme dissociation
through altering the structure of hexokinase. To test this hypothe-
sis, we measured the center of mass of the intrinsic ﬂuorescence
spectrum of puriﬁed hexokinase in the presence or absence of
10 mM lactate (Fig. 6B). This technique is commonly used to eval-
uate the transitions between the intermediate states of proteins in
response, for instance, to ligands [23] or different enzymatic con-
centrations [24,25]. As shown in Fig. 6B, lactate could indeed alter
the structure of hexokinase. This structural alteration was not
Fig. 4. Effect of lactate on the activity and cellular distribution of hexokinase and glucokinase. HK or glucokinase activity was assessed as described in Section 2 in skeletal
muscle (A) and liver (B), respectively. Panel C shows the results after fractionation. Values are presented as the mean ± S.E.M. of six independent assays.
Fig. 5. Effect of lactate on the association of puriﬁed hexokinase to mitochondria in
skeletal muscle. HK activity was assessed as described in Section 2. Values are
presented as the mean ± S.E.M. of three independent assays.
96 T.C. Leite et al. / FEBS Letters 585 (2011) 92–98caused by protein denaturation because the enzymatic activity was
preserved under these experimental conditions (Fig. 6A). Although
these results do not provide a deﬁnitive explanation, they suggest
that lactate can alter the structure of hexokinase and that thismodiﬁcation may lead to the dissociation of the enzyme from
mitochondria and nuclei, which, in turn, causes its inhibition.
The effects of lactate on PK activity was also evaluated. For this
purpose, we used an alternative method for the assay of PF activity,
instead of the classical coupled enzyme linked assay. This was nec-
essary since the classical method uses lactate dehydrogenase to
evaluate the pyruvate formed through its reduction measuring
the coupled oxidation of NADH to NAD+. However, the presence
of lactate in the reaction medium would displace the equilibrium
of this reaction in the opposite direction, interfering with the mea-
surements. To solve this issue, we analyzed the ATP formed using a
commercial kit. The method was efﬁcient but lactate did not pro-
mote any effect on PK activity under all tested conditions (data
not shown).
Our results support the hypothesis that lactate is not a mere
byproduct of glycolysis without relevant metabolic roles. In fact,
several groups have shown that lactate metabolism is highly versa-
tile and associated with several pathological conditions [26–31].
The inhibitory effects of lactate on the enzymes known to be
important in regulating glycolytic ﬂux, such as hexokinase and
PFK, in tissues, such as skeletal muscle and liver, can have a inhib-
itory effect on carbohydrate metabolism [14,15,17]. Because skele-
tal muscle is one of the most important tissues in glucose
metabolism, glycolytic ﬂux inhibition caused by lactate in this tis-
sue, even in the presence of insulin, can have a systemic impact on
hexose metabolism in the whole body [32]. We suggest that the
inhibitory effect of insulin is in part due to (I) antagonistic effects
Fig. 6. Effects of lactate on the activity and structure of puriﬁed hexokinase. (A) HK
activity (A) and intrinsic ﬂuorescence spectra (B) were performed as described in
Section 2. Values are presented as the mean ± S.E.M. of three independent
experiments. *P < 0.05 indicates a statistically signiﬁcant difference between the
experimental group and the control group without lactate.
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biphosphate; (II) decreased phosphorylation level of PFK tyrosine
residues and (III) PFK dimerization that inhibits its activity [9]. Fur-
thermore, hexokinase inhibition occurs mainly through regulating
the association of the enzyme to cellular structures such as mito-
chondrial and nuclear membranes. There is no direct modulation
of hexokinase I by lactate. The modulation of the association with
mitochondrial and nuclear membranes is dependent on the
alteration of the enzyme structure without protein denaturation,
consistent with lactate-induced insulin resistance because the abil-
ity of insulin to increase glucose uptake depends on both GLUT4
externalization and increased mobilization of hexokinase to
mitochondrial membrane [33], an effect antagonized by lactate.
Therefore, we suggest that lactate acts as an antagonist of insulin
regarding hexokinase activity and contributes to the decreased
glucose consumption by skeletal muscle, a common characteristic
under pathological conditions with insulin resistance. In the liver,
lactate modulates the major enzymes of the gluconeogenesis path-
way, thereby contributing to the hyperglycemia characteristic of
diabetes. Finally, our results are in agreement with the theory
supported by several groups that lactate should be recognized as
an extremely versatile molecule, not simply the end product of
fermentation glycolysis.Acknowledgements
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